<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The authors present for the first time the results of investigation and treatment of 55 patients with transitory cerebral circulation disorders (TCCD) and circulatory <z:hpo ids='HP_0001298'>encephalopathy</z:hpo> by the new <z:chebi fb="11" ids="22586">antioxidant</z:chebi> drug emoxipine  </plain></SENT>
<SENT sid="1" pm="."><plain>The drug was noted to produce a beneficial clinical effect in 39 patients </plain></SENT>
<SENT sid="2" pm="."><plain>After emoxipine treatment the patients demonstrated an increase of the endogenous <z:chebi fb="11" ids="22586">antioxidants</z:chebi>, evidence of the formation of the <z:chebi fb="11" ids="22586">antioxidant</z:chebi> depot </plain></SENT>
<SENT sid="3" pm="."><plain>In the patients suffering from TCCD, the content of endogenous <z:chebi fb="11" ids="22586">antioxidants</z:chebi> did not differ from <z:mpath ids='MPATH_458'>normal</z:mpath> both before and after the treatment </plain></SENT>
<SENT sid="4" pm="."><plain>Improvement of the patients' clinical status correlated with the drug dose and changes in <z:chebi fb="23" ids="18059">lipid</z:chebi> peroxidation </plain></SENT>
<SENT sid="5" pm="."><plain>In patients with deterioration of the health status and without any changes, the dose-dependent effect was not recorded </plain></SENT>
</text></document>